Octreotate-Lu-177-DOTA-Tyr-3

Octreotate-Lu-177-DOTA-Tyr-3 Reactions 1680, p263 - 2 Dec 2017 Thrombocytopenia: case report In a retrospective cohort analysis of 167 patients, a patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with octreotate- Lu-177-DOTA-Tyr-3 [ Lu-DOTATATE; duration of treatment to reaction onset not stated]. The patient, who had advanced neuroendocrine tumour, received treatment with 5550 to 7400 MBq (150 200 mCi) of octreotate-Lu-177-DOTA-Tyr-3 diluted in 48 to 50mL of sodium chloride [saline] and infused over 30 minutes with a flow rate of 1.6 mL/minute. The patient received octreotate- Lu-177-DOTA-Tyr-3 after 30 to 60 minutes from the start of amino acid infusion. Before the initiation of treatment, the patient had grade I thrombocytopenia. However, during the course of therapy, the patient exhibited further depletion in the platelet counts (86000 48000 /µL), which was considered as grade III thrombocytopenia. The patient’s decreased platelet count was managed with platelet transfusion. Author comment: "Treatment-related adverse events were analyzed in all the patients." "One patient presented with grade I thrombocytopenia at the time of recruitment and progressed to grade III toxicity." "The platelet counts in this patient were revived through platelet transfusion." Ballal S, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clinical Nuclear Medicine 42: e457-e466, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1097/ RLU.0000000000001816 - India 803284431 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Octreotate-Lu-177-DOTA-Tyr-3

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/octreotate-lu-177-dota-tyr-3-xw4GQomurB
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39194-0
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p263 - 2 Dec 2017 Thrombocytopenia: case report In a retrospective cohort analysis of 167 patients, a patient [age and sex not stated] was described, who developed thrombocytopenia during treatment with octreotate- Lu-177-DOTA-Tyr-3 [ Lu-DOTATATE; duration of treatment to reaction onset not stated]. The patient, who had advanced neuroendocrine tumour, received treatment with 5550 to 7400 MBq (150 200 mCi) of octreotate-Lu-177-DOTA-Tyr-3 diluted in 48 to 50mL of sodium chloride [saline] and infused over 30 minutes with a flow rate of 1.6 mL/minute. The patient received octreotate- Lu-177-DOTA-Tyr-3 after 30 to 60 minutes from the start of amino acid infusion. Before the initiation of treatment, the patient had grade I thrombocytopenia. However, during the course of therapy, the patient exhibited further depletion in the platelet counts (86000 48000 /µL), which was considered as grade III thrombocytopenia. The patient’s decreased platelet count was managed with platelet transfusion. Author comment: "Treatment-related adverse events were analyzed in all the patients." "One patient presented with grade I thrombocytopenia at the time of recruitment and progressed to grade III toxicity." "The platelet counts in this patient were revived through platelet transfusion." Ballal S, et al. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients with Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clinical Nuclear Medicine 42: e457-e466, No. 11, Nov 2017. Available from: URL: http://doi.org/10.1097/ RLU.0000000000001816 - India 803284431 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial